-
公开(公告)号:AU2010262905B2
公开(公告)日:2015-04-16
申请号:AU2010262905
申请日:2010-06-17
Applicant: VERTEX PHARMA
Inventor: CHARIFSON PAUL , CLARK MICHAEL P , BANDARAGE UPUL K , BETHIEL RANDY S , COURT JOHN J , DENG HONGBO , DRUTU IOANA , DUFFY JOHN P , FARMER LUC , GAO HUAI , GU WENXIN , JACOBS DYLAN H , KENNEDY JOSEPH M , LEDEBOER MARK W , LEDFORD BRIAN , MALTAIS FRANCOIS , PEROLA EMANUELE , WANG TIANSHENG , WANNAMAKER M WOODS , BYRN RANDAL , ZHOU YI , LIN CHAO , JIANG MIN , JONES STEVEN , GERMANN URSULA A , SALITURO FRANCESCO G , KWONG ANN DAK-YEE
IPC: A61K31/506 , A61P31/16
Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
-
公开(公告)号:PE20120508A1
公开(公告)日:2012-05-09
申请号:PE2011002120
申请日:2010-06-17
Applicant: VERTEX PHARMA
Inventor: CHARIFSON PAUL , CLARK MICHAEL P , BANDARAGE UPUL K , BETHIEL RANDY S , COURT JOHN J , DENG HONGO , DRUTU IONA , DUFFY JOHN P , FARMER LUC , GAO HUAI , GU WEXIN , JACOBS DYLAN H , KENNEDY JOSEPH M , LEDEBOER MARK W , LEDFORD BRIAN , MALTAIS FRANCOIS , PEROLA EMANUELE , WANG TIANSHENG , WANNAMAKER M WOODS , BYRN RANDAL , ZHOU YI , LIN CHAO , JIANG MIN , JONES STEVEN , GERMANN URSULA A , SALITURO FRANCESCO G , KWONG ANN DAK-YEE
IPC: C07D471/04 , A61K31/437 , A61P31/16
Abstract: REFERIDA A UN DERIVADO DE PIRROLOPIRIDINA DE FORMULA (IA), DONDE Z1 ES F, Cl, CN, NO2, ENTRE OTROS; Z2 ES R*, OR*, CO2R*, ENTRE OTROS; Z3 ES H, OH, NH2, HALOGENO, ENTRE OTROS; R1 ES H O ALQUILO C1-C6; R2 ES H, F, NH2, NH(ALQUILO C1-C4), ENTRE OTROS; R3 ES H, Cl, F, OH, O(ALQUILO C1-C4), ENTRE OTROS; R4 ES (a), (b) O (c); T ES UN CARBOCICLO NO AROMATICO C3-C10 OPCIONALMENTE SUSTITUIDO CON JA O UN HETEROCICLO NO AROMATICO DE 3 A 10 MIEMBROS OPCIONALMENTE SUSTITUIDO CON JB; J ES UN HETEROCICLO NO AROMATICO DE 3 A 10 MIEMBROS OPCIONALMENTE SUSTITUIDO CON JB; D ES UN HETEROCICLO NO AROMATICO DE 4 A 10 MIEMBROS OPCIONALMENTE SUSTITUIDO CON JD1; JA Y JB SON HALOGENO, CN, NCO, ENTRE OTROS; R9 ES H, HALOGENO, CN, OH, AMINO, ALQUILO C1-C6, ENTRE OTROS; R* ES H, ALQUILO C1-C6, CARBOCICLO C3-C8 NO AROMATICO, ENTRE OTROS; JD1 ES HALOGENO, CN, OXO, ENTRE OTROS; R13 Y R14 SON H, HALOGENO, ALQUILO C1-C6, ENTRE OTROS; j Y z SON 1 O 2; t ES 0, 1 O 2. SON COMPUESTOS PREFERIDOS: ACIDO (R)-3-(3-((2-(5-CLORO-1H-PIRROLO[2,3-b]PIRIDIN-3-IL)-5-FLUOROPIRIMIDIN-4-ILAMINO)METIL)PIPERIDINA-1-CARBONIL)PIRAZINA-2-CARBOXILICO, (S)-1-(3-((2-(5-CLORO-1H-PIRROLO[2,3-b]PIRIDIN-3-IL)-5-FLUOROPIRIMIDIN-4-ILAMINO)METIL)PIPERIDIN-1-IL)-2-METOXIETANONA, (S)-1-(3-((2-(5-CLORO-1H-PIRROLO[2,3-b]PIRIDIN-3-IL)-5-FLUOROPIRIMIDIN-4-ILAMINO)METIL)PIPERIDIN-1-IL)PROPAN-1-ONA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS INHIBEN LA REPLICACION DEL VIRUS DE LA INFLUENZA
-
公开(公告)号:AU2003245442B2
公开(公告)日:2009-02-05
申请号:AU2003245442
申请日:2003-06-11
Applicant: VERTEX PHARMA
Inventor: DRUMM JOSEPH , STAMOS DEAN , LIAO YUSHENG , DEININGER DAVID D , GRILLOT ANNE-LAURE , OLIVER-SHAFFER PATRICIA , CHARIFSON PAUL
IPC: A61K31/4439 , A61K31/444 , A61K31/50 , A61K31/506 , A61K45/00 , A61K45/06 , A61P1/04 , A61P11/00 , A61P13/02 , A61P13/08 , A61P17/00 , A61P27/16 , A61P31/04 , A61P43/00 , C07C275/06 , C07D401/04 , C07D401/14 , C07D403/04
Abstract: The present invention relates to compounds which inhibit bacterial gyrase and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals. The present invention also relates to a method for preparing these compounds.
-
公开(公告)号:AT410439T
公开(公告)日:2008-10-15
申请号:AT99912662
申请日:1999-03-19
Applicant: VERTEX PHARMA
Inventor: WANNAMAKER MARION , BEMIS GUY , CHARIFSON PAUL , LAUFFER DAVID , MULLICAN MICHAEL , MURCKO MARK , WILSON KEITH , JANETKA JAMES , DAVIES ROBERT , GRILLOT ANNE-LAURE , SHI ZHAN , FORSTER CORNELIA
IPC: C07D207/273 , C07K5/023 , A61K31/47 , A61K38/00 , A61K38/03 , A61K38/04 , A61P5/48 , A61P7/00 , A61P9/00 , A61P17/00 , A61P19/00 , A61P19/08 , A61P19/10 , A61P25/00 , A61P29/00 , A61P31/04 , A61P35/00 , A61P37/00 , A61P37/06 , A61P43/00 , C07D401/12 , C07K5/02
Abstract: The present invention relates to novel classes of compounds which are caspase inhibitors, in particular interleukin-1² converting enzyme ("ICE") inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting caspase activity and consequently, may be advantageously used as agents against interleukin-1- ("IL-1"), apoptosis-, interferon-³ inducing factor-(IGIF), or interferon-³-("IFN-³") mediated diseases, including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases. This invention also relates to methods for inhibiting caspase activity and decreasing IGIF production and IFN-³ production and methods for treating interieukin-1, apoptosis-, and interferon-³ mediated diseases using the compounds and compositions of this invention. This invention also relates to methods of preparing the compounds of this invention.
-
公开(公告)号:ES2294046T3
公开(公告)日:2008-04-01
申请号:ES01994269
申请日:2001-12-12
Applicant: VERTEX PHARMA
Inventor: GRILLOT ANNE-LAURE , CHARIFSON PAUL , STAMOS DEAN , LIAO YUSHENG , BADIA MICHAEL , TRUDEAU MARTIN
IPC: C07D235/30 , C07D235/32 , A61K31/00 , A61K31/4184 , A61K31/423 , A61K31/4245 , A61K31/437 , A61K31/4412 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4709 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K45/06 , A61P31/00 , A61P31/04 , A61P43/00 , C07D213/00 , C07D221/00 , C07D235/00 , C07D263/58 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/04 , C07D413/04 , C07D471/04 , C07D471/14 , C07D491/04 , C07D491/056 , C07D498/04 , C07D521/00 , C07F9/6558 , C07F9/6561
Abstract: Un método para disminuir la cantidad bacteriana en una muestra biológica ex vivo que comprende el paso de poner en contacto la muestra biológica con un compuesto de la fórmula I: o una sal farmacéuticamente aceptable de la misma, en donde: Z es 0 o N-R4; W es nitrógeno o CRa; Ra se selecciona de hidrógeno, halógeno, -CF3, R7, -OR7, o -N(R7)2;R1 es un anillo de arilo o heteroarilo, en donde el anillo se sustituye opcionalmente hasta por cuatro R9; en donde un sustituyente R9 en la posicion orto de R1 tomado junto con R2 puede formar un anillo de 5-8 miembros fusionado, sustituido opcionalrnente insaturado o parcialmente insaturado, que tiene 0-2 heteroátomos en el anillo seleccionados de nitrógeno, oxígeno, o azufre; R2 y R3 cada uno independientemente se seleccionan de R6, halógeno, CN, SR6, OR6, N(R6)2, CON(R6)2, COR6, CO2R6, COCOR6, SO2R6, SO2N(R6)2, o R2 y R3 se toman juntos para formars un anillo de 5-8 miembros fusionado, insaturado o parcialmente insaturado, opcionalmente substituido, que contiene 0-2 heteroátomos en anillo seleccionados de nitrógenos, oxígeno o azufre; R4 se selcciona de R6, CON(R6), COR6, CO2R6, COCOR6, SO2R6, SO2N(R6)2, o (CH2)yR2 ; y es 1-6; R5 se selecciona de R7, Ar, COAr, CON(R7)Ar, (CH2)yN(R7)2, C(=NR10)-N(R7)2, C(=S)-N(R7)2, CON(R7)2, o SO2N(R7)2; Ar es un anillo de cinco miembros de heteroarilo, heterociclilo, o carbociclilo, donde dicho anillo se sustituye opcionalmente hasta por tres sustituyentes seleccionados de oxo, halógeno, CN, NO2, R8, OR8, NHR8, NHCOR8, NHCONHR8, COR8, CONHR8, SO2R8, NHSO2NHR8 o SO2NHR8 ; cada R6 se selecciona independientemente de R7 o un grupo opcionalmente sustituido seleccionado de alcoxi, hidroxialquilo, heterociclilo, heterociclilalquilo, arilo, aralquilo, aralcoxi, ariloxialquilo, heteroarilo, heteroaralquilo, heteroaralcoxi, o heteroariloxialquilo; cada R7 se selecciona independientemente de hidrógeno o un grupo opcionalmente sustituido que tiene uno a seis carbonos, o dos R7 en el mismo nitrógeno tomado junto con el nitrógeno opcionalmente forman un anillo heterocíclico de cuatro a seis miembros, saturado o insaturado que tiene uno a tres heteroátomos; R8 es un grupo alifático de C1-C4, donde dos R8 en posiciones adyacentes de Ar, o un anillo de arilo o heteroarilo, pueden tomarse juntos con sus átomos que intervienen para formar un anillo fusionado de tres a seis miembros;
-
公开(公告)号:SI1341769T1
公开(公告)日:2008-02-29
申请号:SI200130794
申请日:2001-12-12
Applicant: VERTEX PHARMA
Inventor: GRILLOT ANNE-LAURE , CHARIFSON PAUL , STAMOS DEAN , LIAO YUSHENG , BADIA MICHAEL , TRUDEAU MARTIN
IPC: C07D235/00 , C07D235/32 , A61K31/00 , A61K31/4184 , A61K31/423 , A61K31/4245 , A61K31/437 , A61K31/4412 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4709 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K45/00 , A61K45/06 , A61P31/00 , A61P31/04 , A61P43/00 , C07D213/00 , C07D221/00 , C07D235/30 , C07D263/00 , C07D263/58 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/00 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/04 , C07D413/00 , C07D413/04 , C07D471/04 , C07D471/14 , C07D491/04 , C07D491/056 , C07D498/04 , C07D521/00 , C07F9/6558 , C07F9/6561
-
公开(公告)号:DK1341769T3
公开(公告)日:2008-01-28
申请号:DK01994269
申请日:2001-12-12
Applicant: VERTEX PHARMA
Inventor: GRILLOT ANNE-LAURE , CHARIFSON PAUL , STAMOS DEAN , BADIA MICHAEL , LIAO YUSHENG , TRUDEAU MARTIN
IPC: C07D235/30 , C07D235/32 , A61K31/00 , A61K31/4184 , A61K31/423 , A61K31/4245 , A61K31/437 , A61K31/4412 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4709 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K45/06 , A61P31/00 , A61P31/04 , A61P43/00 , C07D213/00 , C07D221/00 , C07D235/00 , C07D263/58 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/04 , C07D413/04 , C07D471/04 , C07D471/14 , C07D491/04 , C07D491/056 , C07D498/04 , C07D521/00 , C07F9/6558 , C07F9/6561
Abstract: The present invention relates to compounds of the formula I or a pharmaceutically acceptable derivative thereof. The compounds are useful as inhibitors of bacterial gyrase activity. The present invention also relates to methods for treating bacterial infections in mammals. The present invention also relates to methods for decreasing bacterial quantity in a biological sample.
-
公开(公告)号:AT375983T
公开(公告)日:2007-11-15
申请号:AT01994269
申请日:2001-12-12
Applicant: VERTEX PHARMA
Inventor: GRILLOT ANNE-LAURE , CHARIFSON PAUL , STAMOS DEAN , LIAO YUSHENG , BADIA MICHAEL , TRUDEAU MARTIN
IPC: C07D235/30 , C07D235/32 , A61K31/00 , A61K31/4184 , A61K31/423 , A61K31/4245 , A61K31/437 , A61K31/4412 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4709 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K45/06 , A61P31/00 , A61P31/04 , A61P43/00 , C07D213/00 , C07D221/00 , C07D235/00 , C07D263/58 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/04 , C07D413/04 , C07D471/04 , C07D471/14 , C07D491/04 , C07D491/056 , C07D498/04 , C07D521/00 , C07F9/6558 , C07F9/6561
Abstract: The present invention relates to compounds of the formula I or a pharmaceutically acceptable derivative thereof. The compounds are useful as inhibitors of bacterial gyrase activity. The present invention also relates to methods for treating bacterial infections in mammals. The present invention also relates to methods for decreasing bacterial quantity in a biological sample.
-
公开(公告)号:DE60309701T2
公开(公告)日:2007-09-06
申请号:DE60309701
申请日:2003-06-11
Applicant: VERTEX PHARMA
Inventor: CHARIFSON PAUL , DEININGER D , DRUMM JOSEPH , GRILLOT ANNE-LAURE , LIAO YUSHENG , OLIVER-SHAFFER PATRICIA , STAMOS DEAN
IPC: A61K31/4439 , A61K31/444 , A61K31/50 , A61K31/506 , A61K45/00 , A61K45/06 , A61P1/04 , A61P11/00 , A61P13/02 , A61P13/08 , A61P17/00 , A61P27/16 , A61P31/04 , A61P43/00 , C07C275/06 , C07C275/64 , C07D401/04 , C07D401/14 , C07D403/04
Abstract: The present invention relates to compounds which inhibit bacterial gyrase and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals. The present invention also relates to a method for preparing these compounds.
-
公开(公告)号:ES2277088T3
公开(公告)日:2007-07-01
申请号:ES03739082
申请日:2003-06-11
Applicant: VERTEX PHARMA
Inventor: CHARIFSON PAUL , DEININGER DAVID D , DRUMM JOSEPH , GRILLOT ANNE-LAURE , LIAO YUSHENG , OLIVER-SHAFFER PATRICIA
IPC: A61K31/4439 , A61K31/444 , A61K31/50 , A61K31/506 , A61K45/00 , A61K45/06 , A61P1/04 , A61P11/00 , A61P13/02 , A61P13/08 , A61P17/00 , A61P27/16 , A61P31/04 , A61P43/00 , C07C275/06 , C07C275/64 , C07D401/04 , C07D401/14 , C07D403/04
Abstract: Un compuesto de la **fórmula** o una sal farmacéuticamente aceptable del mismo, en el que: Q es -NH-; W es C-R4; X es CH; R1 es un anillo arilo de 5-6 miembros que tiene 1-3 heteroátomos que se seleccionan independientemente de oxígeno, nitrógeno o azufre, en el que: R1 está sustituido con 0-3 grupos que se seleccionan independientemente de R, oxo, CO2R'', OR'', N(R'')2, SR'', NO2, halógeno, CN, C(O)N(R'')2, NR''C(O)R'', SO2R'', SO2N(R'')2, o NR''SO2R''.
-
-
-
-
-
-
-
-
-